Ruxolitinib Safety Experience In The Polycythemia Vera Clinical Trial Program.

Srdan Verstovsek,Ruben A. Mesa,Bruno Martino,Jean-Jacques Kiladjian,Mark M. Jones,Shui He,Dany Habr,Iulian Alecu,Alessandro M. Vannucchi

Journal of Clinical Oncology（2015）

引用 0|浏览13

暂无评分

摘要

e18082 Background: Polycythemia vera (PV) is associated with over-activation of the JAK/STAT pathway and characterized by erythrocytosis and an increased risk of thrombosis. Some patients (pts) may...

查看译文

关键词

polycythemia vera,clinical trial,clinical trial program

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要